Fig. 3: Clinical assessment of response to neoadjuvant pembrolizumab.
a, Examples of clinical response noted after three cycles of pembrolizumab. A representative patient with a scalp lesion (top) and a representative patient with a back lesion (bottom) are shown. The pictures were obtained and published with patient written consent. b, Waterfall plot demonstrating the clinical response after 9 weeks of pembrolizumab (n = 22, excluding three patients who were not assessable for response). Clinical response was assessed radiographically or by clinical exam with photos. The vertical bars represent the percentage increase or decrease in the size of target lesions against baseline. Lines indicate the threshold for objective response (≥30% decrease) or disease progression (>20% increase); SD, stable disease.
